先天性淋巴细胞
医学
原发性胆汁性肝硬化
免疫学
发病机制
肿瘤坏死因子α
自身免疫
炎症
内科学
内分泌学
抗体
免疫系统
先天免疫系统
作者
Yansheng Liu,Yinan Hu,Bo Li,Rui Su,Zheyi Han,Boquan Jin,Ting Li,Xiaohong Zheng,Ying Han
摘要
Abstract Background and Aim Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by destructive lymphocytic cholangitis and specific anti‐mitochondrial antibodies. Innate lymphoid cells (ILCs) have been reported to play a role in liver homeostasis and autoimmunity. Methods We evaluated the features of peripheral ILC1s and ILC3 in patients with PBC and hepatic ILC1 and ILC3 in two different PBC mouse models (dominant‐negative transforming growth factor‐beta receptor II [dnTGFβRII] and 2‐octynoic acid‐bovine serum albumin [2OA‐BSA]). Results A total of 115 patients and 18 healthy controls were enrolled in the study. Decreased circulating ILC1/3s were observed in early‐stage PBC patients, and the numbers of ILC1/3s were negatively correlated with specific parameters and the proportion of T‐helper (Th) 1 and Th17 cells. Reduced numbers of ILC1s were observed in PBC mouse models with different etiologies. ILC1‐deficient mice had more severe hepatic inflammation after inducing the 2OA‐BSA model. Continuous low‐dose injections of lipopolysaccharide (LPS) reduced ILC1 levels in mice, consistent with the lower level of ILC1s in PBC patients with high LPS (> 50 ng/mL), and aggravated hepatic lymphocyte infiltration. Conclusion Patients with PBC had decreased ILC1s, which were negatively correlated with CD4 + T cells. Deficient ILC1 populations led to disease exacerbations in mice. Our results indicated that ILC1s may participate in the pathogenesis of PBC.
科研通智能强力驱动
Strongly Powered by AbleSci AI